Biologics MGR 2017
- TBRC2090
- Pages: 250
- July 2017
- Total Views:1169
- Region : Global
- The Business Research Company
- Market Research Report

Details
Biologics market covers biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnology methods and other cutting-edge technologies.
The global biologics market was estimated to be around $210 billion as of 2016. It made up around 20% of the overall pharmaceuticals market in 2016. The biologics was the second largest market, following the pharmaceutical drugs market in the global pharmaceutical market in 2016.
Treatment of complex diseases
Biologics provide effective treatment for many complex diseases such as Rheumatoid arthritis that have less treatment options. There has been significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan).
The Biologics Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global satellite and telecommunications resellers sector.
Reasons to Purchase
Outperform competitors using accurate up to date demand-side dynamics information.
Identify growth segments for investment.
Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
Create regional and country strategies on the basis of local data and analysis.
Stay abreast of the latest customer and market research findings
Benchmark performance against key competitors.
Develop strategies based on likely future developments.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Gain a global perspective on the development of the market.
Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical market, and compares it with other markets.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
The biologics market section of the report gives context. It compares the biologics market with other segments of the pharmaceutical market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The biologics Indicators Comparison.
The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines
Companies Mentioned: Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Biologics Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table Of Content
Scope
1. Biologics Market Characteristics;
2. Biologics Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Biologics Market Customer Information;
5. Biologics Market Segmentation;
5.1. Global Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 5.2. Global Biologics Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Biologics Market Trends And Strategies; 5.4 Global Biologics Market Compared With Similar Markets, 2016; 5.5 Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast; 5.6 Biologics Market Compared With Similar Markets, 2016, By Region; 5.7 Biologics Market Compared With Similar Markets, 2016, By Country; 5.8 Therapeutic Proteins; 5.8.1. Market Characteristics; 5.8.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.8.3. Market Trends And Strategies; 5.9 Monoclonal Antibodies (MABS); 5.9.1. Market Characteristics; 5.9.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.9.3. Market Trends And Strategies; 5.10 Vaccines; 5.9.1. Market Characteristics; 5.10.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.10.3. Market Trends And Strategies;
6. Biologics Market Regional And Country Analysis;
6.1. Global Biologics Market, 2016, By Region; 6.2. Global Biologics Market, 2012-2020, Historic And Forecast, By Region; 6.3. Biologics Market, 2016, By Country; 6.4. Biologics Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Healthcare Market Segments, 2016, By Region; 6.6. Global Pharmaceuticals Market Segments, 2016, By Region; 6.7. Global Healthcare Market Segments, 2016, By Country; 6.8. Global Pharmaceuticals Market Segments, 2016, By Country;
7. Global Biologics Market Comparison With Macro Economic Factors;
7.1. Biologics Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Biologics Expenditure, Global;
8. Biologics Market Comparison With Macro Economic Factors Across Countries;
8.1. Biologics Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Biologics Expenditure, By Country;
9. Biologics Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Number Of Employees In Pharmaceutical Industry, 2016, By Country; 9.6. Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country; 9.7. Global Average Spending On R&D/Product Development, 2016, By Country; 9.8. Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.9. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.10. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.11. Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country; 9.12. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country; 9.13. Global Number Of Pharmacies, 2016, By Country; 9.14. Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country; 9.15. Global New Drug Approvals, 2016, By Country; 9.16. Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country; 9.17. Prevalent Cases Of Thalassemia, 2014, By Country; 9.18. Global Number Of General Practitioners 2016, By Country; 9.19. Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Biologics Market;
10.1.1. Asia-Pacific Biologics Market Overview; 10.1.2. Asia-Pacific Biologics Historic Market, 2012-2016; 10.1.3. Asia-Pacific Biologics Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.2. Asia-Pacific Biologics Market: Country Analysis; 10.3. China Biologics Market; 10.3.1. China Biologics Market Overview; Average Salaries Of Pharmacists; 10.3.2. China Biologics Historic Market, 2012-2016; 10.3.3. China Biologics Forecast Market, 2016-2020; 10.3.4. China Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.3.5. China Biologics Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Biologics Expenditure, 2012-2020; 10.4. India Biologics Market; 10.4.1. India Biologics Market Overview; Average Salaries Of Pharmacists; 10.4.2. India Biologics Historic Market, 2012-2016; 10.4.3. India Biologics Forecast Market, 2016-2020; 10.4.4. India Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.4.5. India Biologics Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Biologics Expenditure, 2012-2020; 10.5. Japan Biologics Market; 10.5.1. Japan Biologics Market Overview; Average Salaries Of Pharmacists; 10.5.2. Japan Biologics Historic Market, 2012-2016; 10.5.3. Japan Biologics Forecast Market, 2016-2020; 10.5.4. Japan Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.5.5. Japan Biologics Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Biologics Expenditure, 2012-2020; 10.5.7. Japan Biologics Market Comparison With Industry Metrics; 10.5.7.1. Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 10.5.7.2. Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 10.6. Australia Biologics Market; 10.6.1. Australia Biologics Historic Market, 2012-2016; 10.6.2. Australia Biologics Forecast Market, 2016-2020; 10.6.3. Australia Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.6.4. Australia Biologics Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Biologics Expenditure, 2012-2020;
11. Western Europe Biologics Market;
11.1.1. Western Europe Biologics Market Overview; 11.1.2. Western Europe Biologics Historic Market, 2012-2016; 11.1.3. Western Europe Biologics Forecast Market, 2016-2020; 11.1.4. Western Europe Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.2. Western Europe Biologics Market: Country Analysis; 11.3. UK Biologics Market; 11.3.1. UK Biologics Market Overview; Average Salaries Of Pharmacists; 11.3.2. UK Biologics Historic Market, 2012-2016; 11.3.3. UK Biologics Forecast Market, 2016-2020; 11.3.4. UK Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.3.5. UK Biologics Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Biologics Expenditure, 2012-2020; 11.3.7. UK Biologics Market Comparison With Industry Metrics; 11.3.7.1 UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.3.7.2 UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.4. Germany Biologics Market; 11.4.1. Germany Biologics Historic Market, 2012-2016; 11.4.2. Germany Biologics Forecast Market, 2016-2020; 11.4.3. Germany Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.4.4 Germany Biologics Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Biologics Expenditure, 2012-2020; 11.4.6 Germany Biologics Market Comparison With Industry Metrics; 11.4.7.1 Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.4.7.2 Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.5 France Biologics Market; 11.5.1 France Biologics Historic Market, 2012-2016; 11.5.2 France Biologics Forecast Market, 2016-2020; 11.5.3 France Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.5.4 France Biologics Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Biologics Expenditure, 2012-2020; 11.5.6 France Biologics Market Comparison With Industry Metrics; 11.5.6.1 France Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.5.6.2 France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.6. Italy Biologics Market; 11.6.1. Italy Biologics Historic Market, 2012-2016; 11.6.2. Italy Biologics Forecast Market, 2016-2020; 11.6.3. Italy Biologics Market, 2016, By Segment; Therapeutic Proteins; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.6.4. Italy Biologics Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Biologics Expenditure, 2012-2020; 11.6.6. Italy Biologics Market Comparison With Industry Metrics; 11.6.6.1 Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.6.6.2 Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.7. Spain Biologics Market; 11.7.1. Spain Biologics Historic Market, 2012-2016; 11.7.2. Spain Biologics Forecast Market, 2016-2020; 11.7.3. Spain Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.7.4. Spain Biologics Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Biologics Expenditure, 2012-2020; 11.7.6. Spain Biologics Market Comparison With Industry Metrics; 11.7.6.1 Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.7.6.2 Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016;
12. Eastern Europe Biologics Market;
12.1.1. Eastern Europe Biologics Market Overview; 12.1.2. Eastern Europe Biologics Historic Market, 2012-2016; 12.1.3. Eastern Europe Biologics Forecast Market, 2016-2020; 12.1.4 Eastern Europe Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 12.2. Eastern Europe Biologics Market: Country Analysis; 12.3. Russia Biologics Market; 12.3.1. Russia Biologics Historic Market, 2012-2016; 12.3.2. Russia Biologics Forecast Market, 2016-2020; 12.3.3. Russia Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 12.3.4. Russia Biologics Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Biologics Expenditure, 2012-2020;
13. North America Biologics Market;
13.1.1. North America Biologics Market Overview; 13.1.2. North America Biologics Historic Market, 2012-2016; 13.1.3. North America Biologics Forecast Market, 2016-2020; 13.1.4. North America Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 13.2. North America Biologics Market: Country Analysis; 13.3. USA Biologics Market; 13.3.1. USA Biologics Historic Market, 2012-2016; 13.3.2. USA Biologics Forecast Market, 2016-2020; 13.3.3 USA Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 13.3.4. USA Biologics Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Biologics Expenditure, 2012-2020; 13.3.6. USA Biologics Market Comparison With Industry Metrics; 13.3.6.1 USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 13.3.6.2 USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016;
14. South America Biologics Market;
14.1.1. South America Biologics Market Overview; 14.1.2. South America Biologics Historic Market, 2012-2016; 14.1.3. South America Biologics Forecast Market, 2016-2020; 14.1.4. South America Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 14.2. South America Biologics Market: Country Analysis; 14.3. Brazil Biologics Market; 14.3.1. Brazil Biologics Historic Market, 2012-2016; 14.3.2. Brazil Biologics Forecast Market, 2016-2020; 14.3.3. Brazil Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 14.3.4. Brazil Biologics Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Biologics Expenditure, 2012-2020;
15. Middle East Biologics Market;
15.1.1. Middle East Biologics Market Overview; 15.1.2. Middle East Biologics Historic Market, 2012-2016; 15.1.3. Middle East Biologics Forecast Market, 2016-2020; 15.1.4. Middle East Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines;
16.1.1. Africa Biologics Market Overview; 16.1.2. Africa Biologics Historic Market, 2012-2016; 16.1.3. Africa Biologics Forecast Market, 2016-2020; 16.1.4. Africa Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines;
17. Biologics Market Competitive Landscape;
17.1. Company Profiles; 17.2. Johnson & Johnson; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Pfizer Inc.; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Novartis Ag; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Abbvie; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Sanofi; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Biologics Market;
19. Market Background: Pharmaceuticals Market;
19.1.1. Pharmaceutical Market Characteristics; 19.1.2. Pharmaceutical Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Trends And Strategies; 19.2. Pharmaceutical Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Market, 2016, By Region; 19.2.2. Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Market, 2016, By Country; 19.2.4. Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceuticals Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Expenditure, Global; 19.4. Pharmaceutical Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
List Of Figure
Table 1: Global Biologics Historic Market Growth
Table 2: Global Biologics Forecast Market Growth
Table 3: Biologics Market Segmentation
Table 4: Global Biologics Market, 2016, By Segment
Table 5: Global Biologics Market, 2012-2020, Historic And Forecast, By Segment
Table 6: Global Biologics Market Compared With Similar Markets, 2016
Table 7: Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast
Table 8: Biologics Market Compared With Similar Markets, 2016, By Region
Table 9: Biologics Market Compared With Similar Markets, 2016, By Country
Table 10: Global Therapeutic Proteins Market, 2016, By Segment
Table 11: Global Monoclonal Antibodies (MABS) Market, 2016, By Segment
Table 12: Global Vaccines Market, 2016, By Segment
Table 13: Global Biologics Market, 2016, By Region
Table 14: Global Biologics Market, 2012-2020, Historic And Forecast, By Region
Table 15: Biologics Market, 2016, By Country
Table 16: Biologics Market, 2012-2020, Historic And Forecast, By Country
Table 17: Global Healthcare Market Segments, 2016, By Region
Table 18: Global Pharmaceuticals Market Segments, 2016, By Region
Table 19: Global Healthcare Market Segments, 2016, By Country
Table 20: Global Pharmaceuticals Market Segments, 2016, By Country;
Table 21: Biologics Market Size, Percentage Of GDP, Global
Table 22: Per Capita Average Biologics Expenditure, Global
Table 23: Biologics Market Comparison With Macro Economic Factors Across Countries
Table 24: Biologics Market Size, Percentage Of GDP, By Country
Table 25: Per Capita Average Biologics Expenditure, By Country
Table 26: Global Number Of Pharmacists, 2016, By Country
Table 27: Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country
Table 28: Global Number Of Pharma Enterprises, 2016, By Country
Table 29: Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Table 30: Global Number Of Employees In Pharmaceutical Industry, 2016, By Country
Table 31: Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country
Table 32: Global Average Spending On R&D/Product Development, 2016, By Country
Table 33: Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Table 34: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 35: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 36: Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
Table 37: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
Table 38: Global Number Of Pharmacies, 2016, By Country
Table 39: Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country
Table 40: Global New Drug Approvals, 2016, By Country
Table 41: Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country
Table 42: Prevalent Cases Of Thalassemia, 2014, By Country
Table 43: Global Number Of General Practitioners 2016, By Country
Table 44: Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country
Table 45: Asia-Pacific Biologics Historic Market, 2012-2016
Table 46: Asia-Pacific Biologics Forecast Market, 2016-2020
Table 47: Asia-Pacific Biologics Market, 2016, By Segment
Table 48: China Biologics Historic Market, 2012-2016
Table 49: China Biologics Forecast Market, 2016-2020
Table 50: China Biologics Market, 2016, By Segment
Table 51: China Biologics Percentage Of GDP, 2012-2020
Table 52: China Per Capita Average Biologics Expenditure, 2012-2020
Table 53: India Biologics Historic Market, 2012-2016
Table 54: India Biologics Forecast Market, 2016-2020
Table 55: India Biologics Market, 2016, By Segment
Table 56: India Biologics Percentage Of GDP, 2012-2020
Table 57: India Per Capita Average Biologics Expenditure, 2012-2020
Table 58: Japan Biologics Historic Market, 2012-2016
Table 59: Japan Biologics Forecast Market, 2016-2020
Table 60: Japan Biologics Market, 2016, By Segment
Table 61: Japan Biologics Percentage Of GDP, 2012-2020
Table 62: Japan Per Capita Average Biologics Expenditure, 2012-2020
Table 63: Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 64: Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 65: Australia Biologics Historic Market, 2012-2016
Table 66: Australia Biologics Forecast Market, 2016-2020
Table 67: Australia Biologics Market, 2016, By Segment
Table 68: Australia Biologics Percentage Of GDP, 2012-2020
Table 69: Australia Per Capita Average Biologics Expenditure, 2012-2020
Table 70: Western Europe Biologics Historic Market, 2012-2016
Table 71: Western Europe Biologics Forecast Market, 2016-2020
Table 72: Western Europe Biologics Market, 2016, By Segment
Table 73: UK Biologics Historic Market, 2012-2016
Table 74: UK Biologics Forecast Market, 2016-2020
Table 75: UK Biologics Market, 2016, By Segment
Table 76: UK Biologics Percentage Of GDP, 2012-2020
Table 77: UK Per Capita Average Biologics Expenditure, 2012-2020
Table 78: UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 79: UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 80: Germany Biologics Historic Market, 2012-2016
Table 81: Germany Biologics Forecast Market, 2016-2020
Table 82: Germany Biologics Market, 2016, By Segment
Table 83: Germany Biologics Percentage Of GDP, 2012-2020
Table 84: Germany Per Capita Average Biologics Expenditure, 2012-2020
Table 85: Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 86: Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 87: France Biologics Historic Market, 2012-2016
Table 88: France Biologics Forecast Market, 2016-2020
Table 89: France Biologics Market, 2016, By Segment
Table 90: France Biologics Percentage Of GDP, 2012-2020
Table 91: France Per Capita Average Biologics Expenditure, 2012-2020
Table 92: France Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 93: France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 94: Italy Biologics Historic Market, 2012-2016
Table 95: Italy Biologics Forecast Market, 2016-2020
Table 96: Italy Biologics Market, 2016, By Segment
Table 97: Italy Biologics Percentage Of GDP, 2012-2020
Table 98: Italy Per Capita Average Biologics Expenditure, 2012-2020
Table 99: Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 100: Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 101: Spain Biologics Historic Market, 2012-2016
Table 102: Spain Biologics Forecast Market, 2016-2020
Table 103: Spain Biologics Market, 2016, By Segment
Table 104: Spain Biologics Percentage Of GDP, 2012-2020
Table 105: Spain Per Capita Average Biologics Expenditure, 2012-2020
Table 106: Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 107: Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 108: Eastern Europe Biologics Historic Market, 2012-2016
Table 109: Eastern Europe Biologics Forecast Market, 2016-2020
Table 110: Eastern Europe Biologics Market, 2016, By Segment
Table 111: Russia Biologics Historic Market, 2012-2016
Table 112: Russia Biologics Forecast Market, 2016-2020
Table 113: Russia Biologics Market, 2016, By Segment
Table 114: Russia Biologics Percentage Of GDP, 2012-2020
Table 115: Russia Per Capita Average Biologics Expenditure, 2012-2020
Table 116: North America Biologics Historic Market, 2012-2016
Table 117: North America Biologics Forecast Market, 2016-2020
Table 118: North America Biologics Market, 2016, By Segment
Table 119: USA Biologics Historic Market, 2012-2016
Table 120: USA Biologics Forecast Market, 2016-2020
Table 121: USA Biologics Market, 2016, By Segment
Table 122: USA Biologics Percentage Of GDP, 2012-2020
Table 123: USA Per Capita Average Biologics Expenditure, 2012-2020
Table 124: USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 125: USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 126: South America Biologics Historic Market, 2012-2016
Table 127: South America Biologics Forecast Market, 2016-2020
Table 128: South America Biologics Market, 2016, By Segment
Table 129: Brazil Biologics Historic Market, 2012-2016
Table 130: Brazil Biologics Forecast Market, 2016-2020
Table 131: Brazil Biologics Market, 2016, By Segment
Table 132: Brazil Biologics Percentage Of GDP, 2012-2020
Table 133: Brazil Per Capita Average Biologics Expenditure, 2012-2020
Table 134: Middle East Biologics Historic Market, 2012-2016
Table 135: Middle East Biologics Forecast Market, 2016-2020
Table 136: Middle East Biologics Market, 2016, By Segment
Table 137: Africa Biologics Historic Market, 2012-2016
Table 138: Africa Biologics Forecast Market, 2016-2020
Table 139: Africa Biologics Market, 2016, By Segment
Table 140: Johnson & Johnson Financial Performance
Table 141: Pfizer Inc. Financial Performance
Table 142: Novartis Ag Financial Performance
Table 143: Abbvie Financial Performance
Table 144: Sanofi Financial Performance
Table 145: Pharmaceutical Market Historic Growth
Table 146: Pharmaceutical Market Forecast Growth
Table 147: Global Pharmaceutical Market, 2016, By Region
Table 148: Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region
Table 149: Pharmaceutical Market, 2016, By Country
Table 150: Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country
Table 151: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment
Table 152: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment;
Table 153: Pharmaceutical Market Size, Percentage Of GDP, Global
Table 154: Per Capita Average Pharmaceutical Expenditure, Global
Table 155: Pharmaceutical Market Comparison With Macro Economic Factors Across Countries
Table 156: Pharmaceutical Market Size, Percentage Of GDP, By Country
Table 157: Per Capita Average Pharmaceutical Expenditure, By Country
Table 158: Pharmaceuticals Industry Financial Margins
List Of Table
Figure 1: Global Biologics Historic Market Growth
Figure 2: Global Biologics Forecast Market Growth
Figure 3: Biologics Market Segmentation
Figure 4: Global Biologics Market, 2016, By Segment
Figure 5: Global Biologics Market, 2012-2020, Historic And Forecast, By Segment
Figure 6: Global Biologics Market Compared With Similar Markets, 2016
Figure 7: Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast
Figure 8: Biologics Market Compared With Similar Markets, 2016, By Region
Figure 9: Biologics Market Compared With Similar Markets, 2016, By Country
Figure 10: Global Therapeutic Proteins Market, 2016, By Segment
Figure 11: Global Monoclonal Antibodies (MABS) Market, 2016, By Segment
Figure 12: Global Vaccines Market, 2016, By Segment
Figure 13: Global Biologics Market, 2016, By Region
Figure 14: Global Biologics Market, 2012-2020, Historic And Forecast, By Region
Figure 15: Biologics Market, 2016, By Country
Figure 16: Biologics Market, 2012-2020, Historic And Forecast, By Country
Figure 17: Global Healthcare Market Segments, 2016, By Region
Figure 18: Global Pharmaceuticals Market Segments, 2016, By Region
Figure 19: Global Healthcare Market Segments, 2016, By Country
Figure 20: Global Pharmaceuticals Market Segments, 2016, By Country;
Figure 21: Biologics Market Size, Percentage Of GDP, Global
Figure 22: Per Capita Average Biologics Expenditure, Global
Figure 23: Biologics Market Comparison With Macro Economic Factors Across Countries
Figure 24: Biologics Market Size, Percentage Of GDP, By Country
Figure 25: Per Capita Average Biologics Expenditure, By Country
Figure 26: Global Number Of Pharmacists, 2016, By Country
Figure 27: Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country
Figure 28: Global Number Of Pharma Enterprises, 2016, By Country
Figure 29: Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Figure 30: Global Number Of Employees In Pharmaceutical Industry, 2016, By Country
Figure 31: Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country
Figure 32: Global Average Spending On R&D/Product Development, 2016, By Country
Figure 33: Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Figure 34: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 35: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 36: Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
Figure 37: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
Figure 38: Global Number Of Pharmacies, 2016, By Country
Figure 39: Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country
Figure 40: Global New Drug Approvals, 2016, By Country
Figure 41: Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country
Figure 42: Prevalent Cases Of Thalassemia, 2014, By Country
Figure 43: Global Number Of General Practitioners 2016, By Country
Figure 44: Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country
Figure 45: Asia-Pacific Biologics Historic Market, 2012-2016
Figure 46: Asia-Pacific Biologics Forecast Market, 2016-2020
Figure 47: Asia-Pacific Biologics Market, 2016, By Segment
Figure 48: China Biologics Historic Market, 2012-2016
Figure 49: China Biologics Forecast Market, 2016-2020
Figure 50: China Biologics Market, 2016, By Segment
Figure 51: China Biologics Percentage Of GDP, 2012-2020
Figure 52: China Per Capita Average Biologics Expenditure, 2012-2020
Figure 53: India Biologics Historic Market, 2012-2016
Figure 54: India Biologics Forecast Market, 2016-2020
Figure 55: India Biologics Market, 2016, By Segment
Figure 56: India Biologics Percentage Of GDP, 2012-2020
Figure 57: India Per Capita Average Biologics Expenditure, 2012-2020
Figure 58: Japan Biologics Historic Market, 2012-2016
Figure 59: Japan Biologics Forecast Market, 2016-2020
Figure 60: Japan Biologics Market, 2016, By Segment
Figure 61: Japan Biologics Percentage Of GDP, 2012-2020
Figure 62: Japan Per Capita Average Biologics Expenditure, 2012-2020
Figure 63: Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 64: Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 65: Australia Biologics Historic Market, 2012-2016
Figure 66: Australia Biologics Forecast Market, 2016-2020
Figure 67: Australia Biologics Market, 2016, By Segment
Figure 68: Australia Biologics Percentage Of GDP, 2012-2020
Figure 69: Australia Per Capita Average Biologics Expenditure, 2012-2020
Figure 70: Western Europe Biologics Historic Market, 2012-2016
Figure 71: Western Europe Biologics Forecast Market, 2016-2020
Figure 72: Western Europe Biologics Market, 2016, By Segment
Figure 73: UK Biologics Historic Market, 2012-2016
Figure 74: UK Biologics Forecast Market, 2016-2020
Figure 75: UK Biologics Market, 2016, By Segment
Figure 76: UK Biologics Percentage Of GDP, 2012-2020
Figure 77: UK Per Capita Average Biologics Expenditure, 2012-2020
Figure 78: UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 79: UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 80: Germany Biologics Historic Market, 2012-2016
Figure 81: Germany Biologics Forecast Market, 2016-2020
Figure 82: Germany Biologics Market, 2016, By Segment
Figure 83: Germany Biologics Percentage Of GDP, 2012-2020
Figure 84: Germany Per Capita Average Biologics Expenditure, 2012-2020
Figure 85: Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 86: Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 87: France Biologics Historic Market, 2012-2016
Figure 88: France Biologics Forecast Market, 2016-2020
Figure 89: France Biologics Market, 2016, By Segment
Figure 90: France Biologics Percentage Of GDP, 2012-2020
Figure 91: France Per Capita Average Biologics Expenditure, 2012-2020
Figure 92: France Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 93: France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 94: Italy Biologics Historic Market, 2012-2016
Figure 95: Italy Biologics Forecast Market, 2016-2020
Figure 96: Italy Biologics Market, 2016, By Segment
Figure 97: Italy Biologics Percentage Of GDP, 2012-2020
Figure 98: Italy Per Capita Average Biologics Expenditure, 2012-2020
Figure 99: Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 100: Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 101: Spain Biologics Historic Market, 2012-2016
Figure 102: Spain Biologics Forecast Market, 2016-2020
Figure 103: Spain Biologics Market, 2016, By Segment
Figure 104: Spain Biologics Percentage Of GDP, 2012-2020
Figure 105: Spain Per Capita Average Biologics Expenditure, 2012-2020
Figure 106: Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 107: Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 108: Eastern Europe Biologics Historic Market, 2012-2016
Figure 109: Eastern Europe Biologics Forecast Market, 2016-2020
Figure 110: Eastern Europe Biologics Market, 2016, By Segment
Figure 111: Russia Biologics Historic Market, 2012-2016
Figure 112: Russia Biologics Forecast Market, 2016-2020
Figure 113: Russia Biologics Market, 2016, By Segment
Figure 114: Russia Biologics Percentage Of GDP, 2012-2020
Figure 115: Russia Per Capita Average Biologics Expenditure, 2012-2020
Figure 116: North America Biologics Historic Market, 2012-2016
Figure 117: North America Biologics Forecast Market, 2016-2020
Figure 118: North America Biologics Market, 2016, By Segment
Figure 119: USA Biologics Historic Market, 2012-2016
Figure 120: USA Biologics Forecast Market, 2016-2020
Figure 121: USA Biologics Market, 2016, By Segment
Figure 122: USA Biologics Percentage Of GDP, 2012-2020
Figure 123: USA Per Capita Average Biologics Expenditure, 2012-2020
Figure 124: USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 125: USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 126: South America Biologics Historic Market, 2012-2016
Figure 127: South America Biologics Forecast Market, 2016-2020
Figure 128: South America Biologics Market, 2016, By Segment
Figure 129: Brazil Biologics Historic Market, 2012-2016
Figure 130: Brazil Biologics Forecast Market, 2016-2020
Figure 131: Brazil Biologics Market, 2016, By Segment
Figure 132: Brazil Biologics Percentage Of GDP, 2012-2020
Figure 133: Brazil Per Capita Average Biologics Expenditure, 2012-2020
Figure 134: Middle East Biologics Historic Market, 2012-2016
Figure 135: Middle East Biologics Forecast Market, 2016-2020
Figure 136: Middle East Biologics Market, 2016, By Segment
Figure 137: Africa Biologics Historic Market, 2012-2016
Figure 138: Africa Biologics Forecast Market, 2016-2020
Figure 139: Africa Biologics Market, 2016, By Segment
Figure 140: Johnson & Johnson Financial Performance
Figure 141: Pfizer Inc. Financial Performance
Figure 142: Novartis Ag Financial Performance
Figure 143: Abbvie Financial Performance
Figure 144: Sanofi Financial Performance
Figure 145: Pharmaceutical Market Historic Growth
Figure 146: Pharmaceutical Market Forecast Growth
Figure 147: Global Pharmaceutical Market, 2016, By Region
Figure 148: Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region
Figure 149: Pharmaceutical Market, 2016, By Country
Figure 150: Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country
Figure 151: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment
Figure 152: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment;
Figure 153: Pharmaceutical Market Size, Percentage Of GDP, Global
Figure 154: Per Capita Average Pharmaceutical Expenditure, Global
Figure 155: Pharmaceutical Market Comparison With Macro Economic Factors Across Countries
Figure 156: Pharmaceutical Market Size, Percentage Of GDP, By Country
Figure 157: Per Capita Average Pharmaceutical Expenditure, By Country
Figure 158: Pharmaceuticals Industry Financial Margins
Licence Rights
- Single User License (for access by one person)
- Site License (for access of one office location of a company)
- Corporate License (allow access by all staff of the company)
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Therapeutic Proteins, Monoclonal Antibodies (MABS), Vaccines
Companies
Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi
Company Profile
Company Profile Title
Biologics market covers biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnology methods and other cutting-edge technologies.
The global biologics market was estimated to be around $210 billion as of 2016. It made up around 20% of the overall pharmaceuticals market in 2016. The biologics was the second largest market, following the pharmaceutical drugs market in the global pharmaceutical market in 2016.
Treatment of complex diseases
Biologics provide effective treatment for many complex diseases such as Rheumatoid arthritis that have less treatment options. There has been significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan).
The Biologics Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global satellite and telecommunications resellers sector.
Reasons to Purchase
Outperform competitors using accurate up to date demand-side dynamics information.
Identify growth segments for investment.
Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
Create regional and country strategies on the basis of local data and analysis.
Stay abreast of the latest customer and market research findings
Benchmark performance against key competitors.
Develop strategies based on likely future developments.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Gain a global perspective on the development of the market.
Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical market, and compares it with other markets.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
The biologics market section of the report gives context. It compares the biologics market with other segments of the pharmaceutical market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The biologics Indicators Comparison.
The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines
Companies Mentioned: Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Biologics Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Scope
1. Biologics Market Characteristics;
2. Biologics Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Biologics Market Customer Information;
5. Biologics Market Segmentation;
5.1. Global Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 5.2. Global Biologics Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Biologics Market Trends And Strategies; 5.4 Global Biologics Market Compared With Similar Markets, 2016; 5.5 Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast; 5.6 Biologics Market Compared With Similar Markets, 2016, By Region; 5.7 Biologics Market Compared With Similar Markets, 2016, By Country; 5.8 Therapeutic Proteins; 5.8.1. Market Characteristics; 5.8.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.8.3. Market Trends And Strategies; 5.9 Monoclonal Antibodies (MABS); 5.9.1. Market Characteristics; 5.9.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.9.3. Market Trends And Strategies; 5.10 Vaccines; 5.9.1. Market Characteristics; 5.10.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.10.3. Market Trends And Strategies;
6. Biologics Market Regional And Country Analysis;
6.1. Global Biologics Market, 2016, By Region; 6.2. Global Biologics Market, 2012-2020, Historic And Forecast, By Region; 6.3. Biologics Market, 2016, By Country; 6.4. Biologics Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Healthcare Market Segments, 2016, By Region; 6.6. Global Pharmaceuticals Market Segments, 2016, By Region; 6.7. Global Healthcare Market Segments, 2016, By Country; 6.8. Global Pharmaceuticals Market Segments, 2016, By Country;
7. Global Biologics Market Comparison With Macro Economic Factors;
7.1. Biologics Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Biologics Expenditure, Global;
8. Biologics Market Comparison With Macro Economic Factors Across Countries;
8.1. Biologics Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Biologics Expenditure, By Country;
9. Biologics Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Number Of Employees In Pharmaceutical Industry, 2016, By Country; 9.6. Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country; 9.7. Global Average Spending On R&D/Product Development, 2016, By Country; 9.8. Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.9. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.10. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.11. Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country; 9.12. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country; 9.13. Global Number Of Pharmacies, 2016, By Country; 9.14. Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country; 9.15. Global New Drug Approvals, 2016, By Country; 9.16. Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country; 9.17. Prevalent Cases Of Thalassemia, 2014, By Country; 9.18. Global Number Of General Practitioners 2016, By Country; 9.19. Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Biologics Market;
10.1.1. Asia-Pacific Biologics Market Overview; 10.1.2. Asia-Pacific Biologics Historic Market, 2012-2016; 10.1.3. Asia-Pacific Biologics Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.2. Asia-Pacific Biologics Market: Country Analysis; 10.3. China Biologics Market; 10.3.1. China Biologics Market Overview; Average Salaries Of Pharmacists; 10.3.2. China Biologics Historic Market, 2012-2016; 10.3.3. China Biologics Forecast Market, 2016-2020; 10.3.4. China Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.3.5. China Biologics Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Biologics Expenditure, 2012-2020; 10.4. India Biologics Market; 10.4.1. India Biologics Market Overview; Average Salaries Of Pharmacists; 10.4.2. India Biologics Historic Market, 2012-2016; 10.4.3. India Biologics Forecast Market, 2016-2020; 10.4.4. India Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.4.5. India Biologics Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Biologics Expenditure, 2012-2020; 10.5. Japan Biologics Market; 10.5.1. Japan Biologics Market Overview; Average Salaries Of Pharmacists; 10.5.2. Japan Biologics Historic Market, 2012-2016; 10.5.3. Japan Biologics Forecast Market, 2016-2020; 10.5.4. Japan Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.5.5. Japan Biologics Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Biologics Expenditure, 2012-2020; 10.5.7. Japan Biologics Market Comparison With Industry Metrics; 10.5.7.1. Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 10.5.7.2. Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 10.6. Australia Biologics Market; 10.6.1. Australia Biologics Historic Market, 2012-2016; 10.6.2. Australia Biologics Forecast Market, 2016-2020; 10.6.3. Australia Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.6.4. Australia Biologics Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Biologics Expenditure, 2012-2020;
11. Western Europe Biologics Market;
11.1.1. Western Europe Biologics Market Overview; 11.1.2. Western Europe Biologics Historic Market, 2012-2016; 11.1.3. Western Europe Biologics Forecast Market, 2016-2020; 11.1.4. Western Europe Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.2. Western Europe Biologics Market: Country Analysis; 11.3. UK Biologics Market; 11.3.1. UK Biologics Market Overview; Average Salaries Of Pharmacists; 11.3.2. UK Biologics Historic Market, 2012-2016; 11.3.3. UK Biologics Forecast Market, 2016-2020; 11.3.4. UK Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.3.5. UK Biologics Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Biologics Expenditure, 2012-2020; 11.3.7. UK Biologics Market Comparison With Industry Metrics; 11.3.7.1 UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.3.7.2 UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.4. Germany Biologics Market; 11.4.1. Germany Biologics Historic Market, 2012-2016; 11.4.2. Germany Biologics Forecast Market, 2016-2020; 11.4.3. Germany Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.4.4 Germany Biologics Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Biologics Expenditure, 2012-2020; 11.4.6 Germany Biologics Market Comparison With Industry Metrics; 11.4.7.1 Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.4.7.2 Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.5 France Biologics Market; 11.5.1 France Biologics Historic Market, 2012-2016; 11.5.2 France Biologics Forecast Market, 2016-2020; 11.5.3 France Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.5.4 France Biologics Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Biologics Expenditure, 2012-2020; 11.5.6 France Biologics Market Comparison With Industry Metrics; 11.5.6.1 France Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.5.6.2 France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.6. Italy Biologics Market; 11.6.1. Italy Biologics Historic Market, 2012-2016; 11.6.2. Italy Biologics Forecast Market, 2016-2020; 11.6.3. Italy Biologics Market, 2016, By Segment; Therapeutic Proteins; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.6.4. Italy Biologics Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Biologics Expenditure, 2012-2020; 11.6.6. Italy Biologics Market Comparison With Industry Metrics; 11.6.6.1 Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.6.6.2 Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.7. Spain Biologics Market; 11.7.1. Spain Biologics Historic Market, 2012-2016; 11.7.2. Spain Biologics Forecast Market, 2016-2020; 11.7.3. Spain Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.7.4. Spain Biologics Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Biologics Expenditure, 2012-2020; 11.7.6. Spain Biologics Market Comparison With Industry Metrics; 11.7.6.1 Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.7.6.2 Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016;
12. Eastern Europe Biologics Market;
12.1.1. Eastern Europe Biologics Market Overview; 12.1.2. Eastern Europe Biologics Historic Market, 2012-2016; 12.1.3. Eastern Europe Biologics Forecast Market, 2016-2020; 12.1.4 Eastern Europe Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 12.2. Eastern Europe Biologics Market: Country Analysis; 12.3. Russia Biologics Market; 12.3.1. Russia Biologics Historic Market, 2012-2016; 12.3.2. Russia Biologics Forecast Market, 2016-2020; 12.3.3. Russia Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 12.3.4. Russia Biologics Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Biologics Expenditure, 2012-2020;
13. North America Biologics Market;
13.1.1. North America Biologics Market Overview; 13.1.2. North America Biologics Historic Market, 2012-2016; 13.1.3. North America Biologics Forecast Market, 2016-2020; 13.1.4. North America Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 13.2. North America Biologics Market: Country Analysis; 13.3. USA Biologics Market; 13.3.1. USA Biologics Historic Market, 2012-2016; 13.3.2. USA Biologics Forecast Market, 2016-2020; 13.3.3 USA Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 13.3.4. USA Biologics Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Biologics Expenditure, 2012-2020; 13.3.6. USA Biologics Market Comparison With Industry Metrics; 13.3.6.1 USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 13.3.6.2 USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016;
14. South America Biologics Market;
14.1.1. South America Biologics Market Overview; 14.1.2. South America Biologics Historic Market, 2012-2016; 14.1.3. South America Biologics Forecast Market, 2016-2020; 14.1.4. South America Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 14.2. South America Biologics Market: Country Analysis; 14.3. Brazil Biologics Market; 14.3.1. Brazil Biologics Historic Market, 2012-2016; 14.3.2. Brazil Biologics Forecast Market, 2016-2020; 14.3.3. Brazil Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 14.3.4. Brazil Biologics Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Biologics Expenditure, 2012-2020;
15. Middle East Biologics Market;
15.1.1. Middle East Biologics Market Overview; 15.1.2. Middle East Biologics Historic Market, 2012-2016; 15.1.3. Middle East Biologics Forecast Market, 2016-2020; 15.1.4. Middle East Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines;
16.1.1. Africa Biologics Market Overview; 16.1.2. Africa Biologics Historic Market, 2012-2016; 16.1.3. Africa Biologics Forecast Market, 2016-2020; 16.1.4. Africa Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines;
17. Biologics Market Competitive Landscape;
17.1. Company Profiles; 17.2. Johnson & Johnson; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Pfizer Inc.; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Novartis Ag; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Abbvie; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Sanofi; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Biologics Market;
19. Market Background: Pharmaceuticals Market;
19.1.1. Pharmaceutical Market Characteristics; 19.1.2. Pharmaceutical Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Trends And Strategies; 19.2. Pharmaceutical Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Market, 2016, By Region; 19.2.2. Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Market, 2016, By Country; 19.2.4. Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceuticals Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Expenditure, Global; 19.4. Pharmaceutical Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
List Of Figure
Table 1: Global Biologics Historic Market Growth
Table 2: Global Biologics Forecast Market Growth
Table 3: Biologics Market Segmentation
Table 4: Global Biologics Market, 2016, By Segment
Table 5: Global Biologics Market, 2012-2020, Historic And Forecast, By Segment
Table 6: Global Biologics Market Compared With Similar Markets, 2016
Table 7: Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast
Table 8: Biologics Market Compared With Similar Markets, 2016, By Region
Table 9: Biologics Market Compared With Similar Markets, 2016, By Country
Table 10: Global Therapeutic Proteins Market, 2016, By Segment
Table 11: Global Monoclonal Antibodies (MABS) Market, 2016, By Segment
Table 12: Global Vaccines Market, 2016, By Segment
Table 13: Global Biologics Market, 2016, By Region
Table 14: Global Biologics Market, 2012-2020, Historic And Forecast, By Region
Table 15: Biologics Market, 2016, By Country
Table 16: Biologics Market, 2012-2020, Historic And Forecast, By Country
Table 17: Global Healthcare Market Segments, 2016, By Region
Table 18: Global Pharmaceuticals Market Segments, 2016, By Region
Table 19: Global Healthcare Market Segments, 2016, By Country
Table 20: Global Pharmaceuticals Market Segments, 2016, By Country;
Table 21: Biologics Market Size, Percentage Of GDP, Global
Table 22: Per Capita Average Biologics Expenditure, Global
Table 23: Biologics Market Comparison With Macro Economic Factors Across Countries
Table 24: Biologics Market Size, Percentage Of GDP, By Country
Table 25: Per Capita Average Biologics Expenditure, By Country
Table 26: Global Number Of Pharmacists, 2016, By Country
Table 27: Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country
Table 28: Global Number Of Pharma Enterprises, 2016, By Country
Table 29: Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Table 30: Global Number Of Employees In Pharmaceutical Industry, 2016, By Country
Table 31: Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country
Table 32: Global Average Spending On R&D/Product Development, 2016, By Country
Table 33: Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Table 34: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 35: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Table 36: Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
Table 37: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
Table 38: Global Number Of Pharmacies, 2016, By Country
Table 39: Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country
Table 40: Global New Drug Approvals, 2016, By Country
Table 41: Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country
Table 42: Prevalent Cases Of Thalassemia, 2014, By Country
Table 43: Global Number Of General Practitioners 2016, By Country
Table 44: Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country
Table 45: Asia-Pacific Biologics Historic Market, 2012-2016
Table 46: Asia-Pacific Biologics Forecast Market, 2016-2020
Table 47: Asia-Pacific Biologics Market, 2016, By Segment
Table 48: China Biologics Historic Market, 2012-2016
Table 49: China Biologics Forecast Market, 2016-2020
Table 50: China Biologics Market, 2016, By Segment
Table 51: China Biologics Percentage Of GDP, 2012-2020
Table 52: China Per Capita Average Biologics Expenditure, 2012-2020
Table 53: India Biologics Historic Market, 2012-2016
Table 54: India Biologics Forecast Market, 2016-2020
Table 55: India Biologics Market, 2016, By Segment
Table 56: India Biologics Percentage Of GDP, 2012-2020
Table 57: India Per Capita Average Biologics Expenditure, 2012-2020
Table 58: Japan Biologics Historic Market, 2012-2016
Table 59: Japan Biologics Forecast Market, 2016-2020
Table 60: Japan Biologics Market, 2016, By Segment
Table 61: Japan Biologics Percentage Of GDP, 2012-2020
Table 62: Japan Per Capita Average Biologics Expenditure, 2012-2020
Table 63: Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 64: Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 65: Australia Biologics Historic Market, 2012-2016
Table 66: Australia Biologics Forecast Market, 2016-2020
Table 67: Australia Biologics Market, 2016, By Segment
Table 68: Australia Biologics Percentage Of GDP, 2012-2020
Table 69: Australia Per Capita Average Biologics Expenditure, 2012-2020
Table 70: Western Europe Biologics Historic Market, 2012-2016
Table 71: Western Europe Biologics Forecast Market, 2016-2020
Table 72: Western Europe Biologics Market, 2016, By Segment
Table 73: UK Biologics Historic Market, 2012-2016
Table 74: UK Biologics Forecast Market, 2016-2020
Table 75: UK Biologics Market, 2016, By Segment
Table 76: UK Biologics Percentage Of GDP, 2012-2020
Table 77: UK Per Capita Average Biologics Expenditure, 2012-2020
Table 78: UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 79: UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 80: Germany Biologics Historic Market, 2012-2016
Table 81: Germany Biologics Forecast Market, 2016-2020
Table 82: Germany Biologics Market, 2016, By Segment
Table 83: Germany Biologics Percentage Of GDP, 2012-2020
Table 84: Germany Per Capita Average Biologics Expenditure, 2012-2020
Table 85: Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 86: Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 87: France Biologics Historic Market, 2012-2016
Table 88: France Biologics Forecast Market, 2016-2020
Table 89: France Biologics Market, 2016, By Segment
Table 90: France Biologics Percentage Of GDP, 2012-2020
Table 91: France Per Capita Average Biologics Expenditure, 2012-2020
Table 92: France Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 93: France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 94: Italy Biologics Historic Market, 2012-2016
Table 95: Italy Biologics Forecast Market, 2016-2020
Table 96: Italy Biologics Market, 2016, By Segment
Table 97: Italy Biologics Percentage Of GDP, 2012-2020
Table 98: Italy Per Capita Average Biologics Expenditure, 2012-2020
Table 99: Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 100: Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 101: Spain Biologics Historic Market, 2012-2016
Table 102: Spain Biologics Forecast Market, 2016-2020
Table 103: Spain Biologics Market, 2016, By Segment
Table 104: Spain Biologics Percentage Of GDP, 2012-2020
Table 105: Spain Per Capita Average Biologics Expenditure, 2012-2020
Table 106: Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 107: Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 108: Eastern Europe Biologics Historic Market, 2012-2016
Table 109: Eastern Europe Biologics Forecast Market, 2016-2020
Table 110: Eastern Europe Biologics Market, 2016, By Segment
Table 111: Russia Biologics Historic Market, 2012-2016
Table 112: Russia Biologics Forecast Market, 2016-2020
Table 113: Russia Biologics Market, 2016, By Segment
Table 114: Russia Biologics Percentage Of GDP, 2012-2020
Table 115: Russia Per Capita Average Biologics Expenditure, 2012-2020
Table 116: North America Biologics Historic Market, 2012-2016
Table 117: North America Biologics Forecast Market, 2016-2020
Table 118: North America Biologics Market, 2016, By Segment
Table 119: USA Biologics Historic Market, 2012-2016
Table 120: USA Biologics Forecast Market, 2016-2020
Table 121: USA Biologics Market, 2016, By Segment
Table 122: USA Biologics Percentage Of GDP, 2012-2020
Table 123: USA Per Capita Average Biologics Expenditure, 2012-2020
Table 124: USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 125: USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Table 126: South America Biologics Historic Market, 2012-2016
Table 127: South America Biologics Forecast Market, 2016-2020
Table 128: South America Biologics Market, 2016, By Segment
Table 129: Brazil Biologics Historic Market, 2012-2016
Table 130: Brazil Biologics Forecast Market, 2016-2020
Table 131: Brazil Biologics Market, 2016, By Segment
Table 132: Brazil Biologics Percentage Of GDP, 2012-2020
Table 133: Brazil Per Capita Average Biologics Expenditure, 2012-2020
Table 134: Middle East Biologics Historic Market, 2012-2016
Table 135: Middle East Biologics Forecast Market, 2016-2020
Table 136: Middle East Biologics Market, 2016, By Segment
Table 137: Africa Biologics Historic Market, 2012-2016
Table 138: Africa Biologics Forecast Market, 2016-2020
Table 139: Africa Biologics Market, 2016, By Segment
Table 140: Johnson & Johnson Financial Performance
Table 141: Pfizer Inc. Financial Performance
Table 142: Novartis Ag Financial Performance
Table 143: Abbvie Financial Performance
Table 144: Sanofi Financial Performance
Table 145: Pharmaceutical Market Historic Growth
Table 146: Pharmaceutical Market Forecast Growth
Table 147: Global Pharmaceutical Market, 2016, By Region
Table 148: Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region
Table 149: Pharmaceutical Market, 2016, By Country
Table 150: Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country
Table 151: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment
Table 152: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment;
Table 153: Pharmaceutical Market Size, Percentage Of GDP, Global
Table 154: Per Capita Average Pharmaceutical Expenditure, Global
Table 155: Pharmaceutical Market Comparison With Macro Economic Factors Across Countries
Table 156: Pharmaceutical Market Size, Percentage Of GDP, By Country
Table 157: Per Capita Average Pharmaceutical Expenditure, By Country
Table 158: Pharmaceuticals Industry Financial Margins
List Of Table
Figure 1: Global Biologics Historic Market Growth
Figure 2: Global Biologics Forecast Market Growth
Figure 3: Biologics Market Segmentation
Figure 4: Global Biologics Market, 2016, By Segment
Figure 5: Global Biologics Market, 2012-2020, Historic And Forecast, By Segment
Figure 6: Global Biologics Market Compared With Similar Markets, 2016
Figure 7: Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast
Figure 8: Biologics Market Compared With Similar Markets, 2016, By Region
Figure 9: Biologics Market Compared With Similar Markets, 2016, By Country
Figure 10: Global Therapeutic Proteins Market, 2016, By Segment
Figure 11: Global Monoclonal Antibodies (MABS) Market, 2016, By Segment
Figure 12: Global Vaccines Market, 2016, By Segment
Figure 13: Global Biologics Market, 2016, By Region
Figure 14: Global Biologics Market, 2012-2020, Historic And Forecast, By Region
Figure 15: Biologics Market, 2016, By Country
Figure 16: Biologics Market, 2012-2020, Historic And Forecast, By Country
Figure 17: Global Healthcare Market Segments, 2016, By Region
Figure 18: Global Pharmaceuticals Market Segments, 2016, By Region
Figure 19: Global Healthcare Market Segments, 2016, By Country
Figure 20: Global Pharmaceuticals Market Segments, 2016, By Country;
Figure 21: Biologics Market Size, Percentage Of GDP, Global
Figure 22: Per Capita Average Biologics Expenditure, Global
Figure 23: Biologics Market Comparison With Macro Economic Factors Across Countries
Figure 24: Biologics Market Size, Percentage Of GDP, By Country
Figure 25: Per Capita Average Biologics Expenditure, By Country
Figure 26: Global Number Of Pharmacists, 2016, By Country
Figure 27: Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country
Figure 28: Global Number Of Pharma Enterprises, 2016, By Country
Figure 29: Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Figure 30: Global Number Of Employees In Pharmaceutical Industry, 2016, By Country
Figure 31: Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country
Figure 32: Global Average Spending On R&D/Product Development, 2016, By Country
Figure 33: Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Figure 34: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 35: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
Figure 36: Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
Figure 37: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
Figure 38: Global Number Of Pharmacies, 2016, By Country
Figure 39: Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country
Figure 40: Global New Drug Approvals, 2016, By Country
Figure 41: Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country
Figure 42: Prevalent Cases Of Thalassemia, 2014, By Country
Figure 43: Global Number Of General Practitioners 2016, By Country
Figure 44: Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country
Figure 45: Asia-Pacific Biologics Historic Market, 2012-2016
Figure 46: Asia-Pacific Biologics Forecast Market, 2016-2020
Figure 47: Asia-Pacific Biologics Market, 2016, By Segment
Figure 48: China Biologics Historic Market, 2012-2016
Figure 49: China Biologics Forecast Market, 2016-2020
Figure 50: China Biologics Market, 2016, By Segment
Figure 51: China Biologics Percentage Of GDP, 2012-2020
Figure 52: China Per Capita Average Biologics Expenditure, 2012-2020
Figure 53: India Biologics Historic Market, 2012-2016
Figure 54: India Biologics Forecast Market, 2016-2020
Figure 55: India Biologics Market, 2016, By Segment
Figure 56: India Biologics Percentage Of GDP, 2012-2020
Figure 57: India Per Capita Average Biologics Expenditure, 2012-2020
Figure 58: Japan Biologics Historic Market, 2012-2016
Figure 59: Japan Biologics Forecast Market, 2016-2020
Figure 60: Japan Biologics Market, 2016, By Segment
Figure 61: Japan Biologics Percentage Of GDP, 2012-2020
Figure 62: Japan Per Capita Average Biologics Expenditure, 2012-2020
Figure 63: Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 64: Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 65: Australia Biologics Historic Market, 2012-2016
Figure 66: Australia Biologics Forecast Market, 2016-2020
Figure 67: Australia Biologics Market, 2016, By Segment
Figure 68: Australia Biologics Percentage Of GDP, 2012-2020
Figure 69: Australia Per Capita Average Biologics Expenditure, 2012-2020
Figure 70: Western Europe Biologics Historic Market, 2012-2016
Figure 71: Western Europe Biologics Forecast Market, 2016-2020
Figure 72: Western Europe Biologics Market, 2016, By Segment
Figure 73: UK Biologics Historic Market, 2012-2016
Figure 74: UK Biologics Forecast Market, 2016-2020
Figure 75: UK Biologics Market, 2016, By Segment
Figure 76: UK Biologics Percentage Of GDP, 2012-2020
Figure 77: UK Per Capita Average Biologics Expenditure, 2012-2020
Figure 78: UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 79: UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 80: Germany Biologics Historic Market, 2012-2016
Figure 81: Germany Biologics Forecast Market, 2016-2020
Figure 82: Germany Biologics Market, 2016, By Segment
Figure 83: Germany Biologics Percentage Of GDP, 2012-2020
Figure 84: Germany Per Capita Average Biologics Expenditure, 2012-2020
Figure 85: Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 86: Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 87: France Biologics Historic Market, 2012-2016
Figure 88: France Biologics Forecast Market, 2016-2020
Figure 89: France Biologics Market, 2016, By Segment
Figure 90: France Biologics Percentage Of GDP, 2012-2020
Figure 91: France Per Capita Average Biologics Expenditure, 2012-2020
Figure 92: France Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 93: France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 94: Italy Biologics Historic Market, 2012-2016
Figure 95: Italy Biologics Forecast Market, 2016-2020
Figure 96: Italy Biologics Market, 2016, By Segment
Figure 97: Italy Biologics Percentage Of GDP, 2012-2020
Figure 98: Italy Per Capita Average Biologics Expenditure, 2012-2020
Figure 99: Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 100: Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 101: Spain Biologics Historic Market, 2012-2016
Figure 102: Spain Biologics Forecast Market, 2016-2020
Figure 103: Spain Biologics Market, 2016, By Segment
Figure 104: Spain Biologics Percentage Of GDP, 2012-2020
Figure 105: Spain Per Capita Average Biologics Expenditure, 2012-2020
Figure 106: Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 107: Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 108: Eastern Europe Biologics Historic Market, 2012-2016
Figure 109: Eastern Europe Biologics Forecast Market, 2016-2020
Figure 110: Eastern Europe Biologics Market, 2016, By Segment
Figure 111: Russia Biologics Historic Market, 2012-2016
Figure 112: Russia Biologics Forecast Market, 2016-2020
Figure 113: Russia Biologics Market, 2016, By Segment
Figure 114: Russia Biologics Percentage Of GDP, 2012-2020
Figure 115: Russia Per Capita Average Biologics Expenditure, 2012-2020
Figure 116: North America Biologics Historic Market, 2012-2016
Figure 117: North America Biologics Forecast Market, 2016-2020
Figure 118: North America Biologics Market, 2016, By Segment
Figure 119: USA Biologics Historic Market, 2012-2016
Figure 120: USA Biologics Forecast Market, 2016-2020
Figure 121: USA Biologics Market, 2016, By Segment
Figure 122: USA Biologics Percentage Of GDP, 2012-2020
Figure 123: USA Per Capita Average Biologics Expenditure, 2012-2020
Figure 124: USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 125: USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016
Figure 126: South America Biologics Historic Market, 2012-2016
Figure 127: South America Biologics Forecast Market, 2016-2020
Figure 128: South America Biologics Market, 2016, By Segment
Figure 129: Brazil Biologics Historic Market, 2012-2016
Figure 130: Brazil Biologics Forecast Market, 2016-2020
Figure 131: Brazil Biologics Market, 2016, By Segment
Figure 132: Brazil Biologics Percentage Of GDP, 2012-2020
Figure 133: Brazil Per Capita Average Biologics Expenditure, 2012-2020
Figure 134: Middle East Biologics Historic Market, 2012-2016
Figure 135: Middle East Biologics Forecast Market, 2016-2020
Figure 136: Middle East Biologics Market, 2016, By Segment
Figure 137: Africa Biologics Historic Market, 2012-2016
Figure 138: Africa Biologics Forecast Market, 2016-2020
Figure 139: Africa Biologics Market, 2016, By Segment
Figure 140: Johnson & Johnson Financial Performance
Figure 141: Pfizer Inc. Financial Performance
Figure 142: Novartis Ag Financial Performance
Figure 143: Abbvie Financial Performance
Figure 144: Sanofi Financial Performance
Figure 145: Pharmaceutical Market Historic Growth
Figure 146: Pharmaceutical Market Forecast Growth
Figure 147: Global Pharmaceutical Market, 2016, By Region
Figure 148: Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region
Figure 149: Pharmaceutical Market, 2016, By Country
Figure 150: Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country
Figure 151: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment
Figure 152: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment;
Figure 153: Pharmaceutical Market Size, Percentage Of GDP, Global
Figure 154: Per Capita Average Pharmaceutical Expenditure, Global
Figure 155: Pharmaceutical Market Comparison With Macro Economic Factors Across Countries
Figure 156: Pharmaceutical Market Size, Percentage Of GDP, By Country
Figure 157: Per Capita Average Pharmaceutical Expenditure, By Country
Figure 158: Pharmaceuticals Industry Financial Margins
- Single User License (for access by one person)
- Site License (for access of one office location of a company)
- Corporate License (allow access by all staff of the company)
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Therapeutic Proteins, Monoclonal Antibodies (MABS), Vaccines
Companies
Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi